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Summary Dermatomyositis (DM) is a multisystem inﬂammatory disorder primarily affecting
the skin and muscles. Its pathophysiology is still very poorly understood, but humoral and cel-
lular immune dysregulation is apparent. Diagnosis of DM is based on ﬁve criteria: proximal
limb muscle weakness, serum muscle enzyme elevation, histopathologic muscle abnormalities
on muscle biopsy, electromyographic abnormalities, and clinical inﬂammatory dermatological
manifestations (heliotrope rash, poikiloderma, and inﬂammatory lesions on the hands and facing
joints). DM is frequently associated with certain cancers, and may appear before, concurrent
with, or after diagnosis of cancer. DM has been reported to be associated with approximately
one per 1000 cases of nasopharyngeal carcinoma. Treatment is based on long-course nonselec-
tive immunosuppression, particularly corticosteroids, by general route, even when malignancy
is present, but new-targeted therapies may modify the treatment strategy in the near future.
Despite iatrogenic immunosuppression, the prognosis of nasopharyngeal cancer is not worse in
patients with paraneoplastic DM. We report one case as an illustration of this paraneoplastic
course (evolving in parallel with the cancer), and to make an update on the state of knowledge
on paraneoplastic DM in such cancers.
© 2010 Elsevier Masson SAS. All rights reserved.∗ Corresponding author.
E-mail address: dana.hartl@igr.fr (D.M. Hartl).
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ermatomyositis (DM) is a multisystem inﬂammatory
isorder primarily affecting the skin and muscles. Its patho-
hysiology is still poorly understood. It is associated with
alignancy in 18—32% of cases, appearing before, simulta-
eously with, or after the diagnosis of cancer [1] DM may
served.
1 A. Chakroun et al.
p
c
a
a
n
a
c
t
a
g
p
c
C
A
s
w
S
A
c
t
n
a
n
l
d
y
M
m
T
m
a
w
t
t
i
N
c
T
a
g
m
w
i
s
m28
arallel the course of the disease, with a paraneoplastic
ourse, or show an independent course. DM is more strongly
ssociated with ovarian, lung and digestive tumors, but has
lso been reported in association with nasopharyngeal carci-
oma (NPC), particularly in the Southeast Asian population,
lthough the incidence of this association is less than 1/1000
ases of NPC, and less than 200 cases have been reported in
he literature [2]. The aim of the present study is to report
case of paraneoplastic DM associated with nasopharyn-
eal cancer, and to illustrate the diagnostic, therapeutic and
rognostic aspects of this entity, of which, despite its rarity,
linicians treating NPC should be aware.
ase report
58-year-old male, born in Cambodia and living in France
ince early adulthood, without previous medical history,
as referred to the Department of ENT Head and Neck
urgery for treatment and diagnostic work up for epistaxis.
nasopharyngeal mass was observed endoscopically. No
linically palpable neck mass was noted. However, derma-
ological abnormalities that had recently appeared were
oted: a rash on photoexposed areas (Fig. 1) with edema
long the eyelid margin (Fig. 2), and poikiloderma on the
eck and the upper chest, with inﬂammatory and erosive
esions on the arms. Imaging and pathological staging led to
iagnosis of an undifferentiated carcinoma of the nasophar-
nx (NPC, World Health Organization type III), stage T3, N1,
0 (one retropharyngeal lymph node) [3].
Treatment consisted of cisplatin and 5-ﬂuorouracil conco-
itant with external beam radiation therapy (64 Grays).
hree weeks into treatment, the patient developed erythe-
atous plaques on his hands, particularly around the nails,
nd complained of disseminated myalgia, proximal muscle
eakness and dyspnea with dysphagia. On physical examina-
ion, muscle strength was normal. Dysphagia was attributed
Figure 1 Heliotrope rash.
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(Figure 2 Rash on forehead and periorbital edema.
o the radiation therapy. Enzymatic testing showed an
ncrease in creatine kinase (3198; N < 195), aldolase (24.9;
< 7.6) and lactate dehydrogenase (716; N < 400). Antinu-
lear, anti-Jo-1 and anti-Ro (SS-A) antibodies were negative.
he diagnosis of DM was based on the clinical characteristics
nd biological ﬁndings, and the association with malignancy.
Treatment with 1mg/kg bodyweight prednisone was
iven as initial therapy, but there was progressive increase in
uscle weakness with associated dysphagia. The treatment
as therefore intensiﬁed by the adjunction of high-dose
ntravenous immunoglobulins, which gave complete regres-
ion of the muscular and cutaneous symptoms. Low-dose
aintenance therapy with prednisone was continued, and
he patient was followed up in the dermatology clinic every
onth and underwent a clinical head and neck examination
very 2 months.
Six months after terminating radiation therapy, the
atient presented worsening of his cutaneous disease, which
as treated with hydroxychloroquine. ENT examination and
RI of the nasopharynx were normal but 18FDG-PET/CT
howed uptake in a left level-II lymph node (subdigastric
ode). The patient underwent modiﬁed radical neck dis-
ection, and pathology conﬁrmed a lymph node metastasis
f the NPC with extracapsular extension. Adjuvant chemo-
adiotherapy re-radiation was performed, and gave clinical,
adiological and PET/CT remission with complete remission
f DM.
The patient was disease-free until 14 months later,
hen the cutaneous manifestations of DM reappeared.
umor recurrence was suspected, and a complete work-
p found a solitary lung nodule in the upper right lobe.
ransthoracic biopsy showed a pulmonary metastasis of NPC,
hich was treated surgically, as the metastasis was sin-
le. Pathologic analysis conﬁrmed the biopsy ﬁndings and
lso found histoplasmosis in adjacent lung tissue. Ketocona-
ole treatment was initiated. The symptoms related to DM
mproved, but cutaneous signs on the face and hands per-
isted.Eight months following surgery, routine PET/CT found
ew lung metastases associated with a 3 cm mediasti-
al lymph node metastasis. Six cycles of chemotherapy
docetaxel, cisplatin, 5-ﬂuorouracil) were administered.
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The patient was still alive with disease, 5 years after initial
diagnosis.
Discussion
NPC accounts for less than 1% of all malignancies and affects
approximately one person in 100,000 in North America and
Western Europe, but is more frequent in Asia and North
Africa, affecting ﬁve to nine per 100,000 of the population
[4]. It is particularly frequent in southern China, totaling
almost one-third of all malignancies treated, according
to Hu et al. [2] It is characterized by the frequency of
an undifferentiated pathological subtype, its relationship
to Epstein-Barr virus with viral DNA detectable in tumor
cells, a high metastatic potential and frequent associa-
tion with paraneoplastic syndromes such as fever, clubbing
osteoarthropathy and leukemoid reactions [5].
DM is an idiopathic inﬂammatory myopathy with promi-
nent and often characteristic cutaneous manifestations.
Patients commonly present with cutaneous disease accom-
panied or shortly followed by proximal muscle weakness. In
the absence of cutaneous disease, the process is known as
polymyositis (PM) [6,7] Bohan and Pete [8] suggested the use
of ﬁve criteria to deﬁne DM-PM: (1) progressive, symmetri-
cal weakness of proximal limb muscles and anterior neck
ﬂexors; (2) dermatological signs (heliotrope rash with peri-
orbital edema, Grotton’s papules (scaly dermatitis on the
joints of ﬁngers), dermatitis on elbows, knees or feet; (3)
muscle biopsy with necrosis of type 1 and 2 ﬁbers, phagocy-
tosis, perifascial atrophy, inﬂammatory exsudate, and other
features; (4) elevatedmuscle enzyme levels (especially CPK,
aldolase and LDH); (5) a particular electromyographic triad
of signs. The presence of three or four criteria plus the rash
is diagnostic for DM, and only two criteria plus the rash are
highly suggestive of DM.
DM may be idiopathic, especially in children, but is also
commonly related to malignancy. In the epidemiological
study by Hill et al., 32% of DMs were associated with can-
cers of the ovary, lung, pancreas, breast or gastrointestinal
tract or non-Hodgkin’s lymphoma [1]. Since the ﬁrst obser-
vation of NPC associated with DM in 1969, more than 160
cases have been reported [9]. The association is rare in Cau-
casians [10—12] but not uncommon in the Far East and North
Africa [2,9,13—16]. Chan reported a series of DM cases in
Singapore, 41% of which were associated with malignancy,
with 60% of the latter being NPC [17]. Hu et al. performed a
statistical study of DM with malignancy in China and found
an incidence of 20.3%, 78.4% of which were NPC; DM was
associated in 0.086% of cases of NPC [2].
The pathogenesis of DM is still poorly understood and
several mechanisms have been suggested. Histologically,
immune complex deposition is seen at the dermal-epidermal
junction. There is an increase in CD4 T cell and B lympho-
cyte levels, and this inﬂammatory inﬁltrate is predominantly
seen in the perivascular regions. Capillary obliteration,
ﬁbrin thrombi and endothelial cell damage are hallmarks
of DM [18]. One theory of the association seen between
DM and malignancy is that tumors express oncoproteins
that stimulate an immune response, and auto-antibodies
are deposited in the skin and muscle where similar anti-
gens may be present. About 30% of patients with DM have
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yositis-speciﬁc antibodies. Three different types of anti-
odies have been recognized: anti-synthetases, anti-signal
ecognition particle antibodies and anti-Mi-2 antibodies
19,20] More recently, the role of type 1 interferons in the
evelopment of both muscular and dermatological manifes-
ations has been shown [21]. A direct relationship between
BV and DM has not been demonstrated. Yamashita, in a
ase report of EBV-associated gastric cancer in a patient with
M, however, speculated that EBV-associated gastric cancer
aused DM as a paraneoplastic syndrome and that EBV may
omehow play a role [22]. Like other autoimmune disorders,
M shows a high incidence of HLA-DR3 and HLA-B8 in human
eukocyte antigens [23,24]. Tumor necrosis factor alpha and
lymphocytes also seem to play major roles in the patho-
hysiology of DM, but the exact involvement of each in the
mmune system remains to be elucidated [25,26].
The treatment of DM in a patient with cancer involves
reating the DM and treating the malignancy. The treatment
f DM is the same in patients with or without associated
alignancy, and mutatis mutandis for the tumor. The goal of
herapy in DM is to enhance muscle strength and to improve
xtramuscular manifestations. There have been very few
ontrolled clinical trials. Treatment remains largely empiric,
sing agents that are non-selective in their effects on the
mmune system [27—30]. Topical emollients and steroids are
mportant for all patients, and may control the skin lesions
ymptomatically until the tumor itself is treated and the
M regresses. If the tumor cannot be treated quickly and
adically, then the patient will probably require oral corti-
osteroids [31].
High-dose intravenous immunoglobulin has shown to be
eneﬁcial for recalcitrant DM [20,32]. Hydroxychloroquine
s quite effective in about 80% of DM patients when used
s a steroid-sparing agent [33]. Immunosuppressors, such as
ethotrexate, azathioprine or cyclosporin, may be effective
n inducing or maintaining remission [34—36] Theoretically,
hese immunosuppressant drugs could exacerbate malig-
ancy, although this does not seem to be the case in
ractice. EBV-associated lymphomas have been reported
n DM patients treated with immunosuppressants [37,38]
ut to our knowledge no case of secondary lymphoma in
patient with both DM and malignancy has been reported.
ost recently, rituximab, a monoclonal antibody directed
gainst the surface antigen CD20 present on most B lympho-
ytes, and used to treat B-cell lymphomas and some severe
orms of lupus and rheumatoid arthritis, has been suggested
or use in DM, following a case report of its efﬁcacy [26].
Many authors have reported that, after complete remis-
ion following radiation therapy for NPC, the symptoms and
hysical signs of DM disappeared or improved, with relapse
f DM correlating to locoregional recurrence or detection
f metastases. Usually the activity of DM mirrors that of
he malignancy. When the patient enters a period of cancer
emission, their DM activity can be used to monitor for early
elapse [39]. There is, however, a subset of cases where DM
oes not reﬂect the treatment and response of the malig-
ancy [31]. Hidano et al. reported that, in their series of
atients, most of the malignancies were temporally related
o the DM, and that 37.3% of the patients improved following
ancer surgery [40]. Cox et al. also reported patients who
howed improvement in their DM with tumor resection and
M relapses concurrent with recurrent tumor [41]. This was
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oted in our present patient, in whom every relapse of DM
as followed by the discovery of a metastasis of the NPC. In
reated patients, side-effects of radiation therapy, such as
ysphagia or skin pigmentation, may mimic a relapse of DM,
o that other cutaneous and muscular signs and symptoms
ust be found to conﬁrm relapse.
The prognosis of NPC with DM has not been shown to be
ifferent from NPC in general, despite immunosuppressive
herapies. In Hu et al.’s case-control study of 90 patients,
ctuarial survival at 5 and 10 years was 50% and 34.5%
espectively for the group of NPC patients with DM ver-
us 57% and 55% respectively for the group of NPC patients
ithout DM, which was not statistically signiﬁcant [2].
onclusion
PC with paraneoplastic DM is a rare but speciﬁc entity.
he diagnosis of DM is based on clinical ﬁndings, abnormal
uscular enzyme titers and negative auto-antibody testing.
he course of DM may follow that of the NPC, but may also
volve independently of the cancer. Side-effects of radiation
herapy may aggravate the symptoms of DM, such as dyspha-
ia and skin inﬂammation, and may also mimic a relapse
f DM in treated patients. The association of DM with
PC does not seem to inﬂuence the prognosis of the can-
er, despite the long-term immunosuppression necessary in
hese patients, so that both affections should be treated
ccordingly and independently by the corresponding special-
sts.
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